Cargando…

Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis

Detalles Bibliográficos
Autores principales:	Capuano, Annalisa, Clementi, Emilio, Paolisso, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692100/ https://www.ncbi.nlm.nih.gov/pubmed/36440009 http://dx.doi.org/10.3389/fcvm.2022.1040649

Ejemplares similares

Editorial: Metabolic Related Cardiomyopathy in Hyperglycemic Patients
por: Capuano, Annalisa, et al.
Publicado: (2022)

Covid-19 Kills More Men Than Women: An Overview of Possible Reasons
por: Capuano, Annalisa, et al.
Publicado: (2020)

In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
por: Cesaro, Arturo, et al.
Publicado: (2022)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2022)

Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review
por: Mascolo, Annamaria, et al.
Publicado: (2020)

Editorial: Epidemiology and clinical researches in atherosclerosis and cardiovascular disease
por: Gao, Darui, et al.
Publicado: (2023)

Editorial: Atherosclerosis and functional imaging
por: Huang, Jei-Yie, et al.
Publicado: (2022)

Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology
por: Wang, Anzhu, et al.
Publicado: (2022)

Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM
por: Li, Lu-Feng, et al.
Publicado: (2021)

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
por: Mascolo, Annamaria, et al.
Publicado: (2022)

Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy
por: Xi, Yangbo, et al.
Publicado: (2022)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
por: Scisciola, Lucia, et al.
Publicado: (2022)

Is There a Diabetes–Kidney–Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors
por: Bao, Liwen, et al.
Publicado: (2021)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
por: Mascolo, Annamaria, et al.
Publicado: (2023)

SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function
por: Maejima, Yasuhiro
Publicado: (2020)

Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Qiu, Mei, et al.
Publicado: (2021)

Editorial: The molecular mechanisms and therapeutic targets of atherosclerosis
por: Gualtierotti, Roberta, et al.
Publicado: (2023)

Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
por: Dzaye, Omar, et al.
Publicado: (2022)

Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse
por: Salim, Hotimah Masdan, et al.
Publicado: (2016)

Contrast-Induced Acute Kidney Injury in Patients on SGLT2 Inhibitors Undergoing Percutaneous Coronary Interventions: A Propensity-Matched Analysis
por: Hua, Rui, et al.
Publicado: (2022)

Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study
por: Frundi, Devine S., et al.
Publicado: (2022)

SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhao, Zinan, et al.
Publicado: (2022)

Diabetic retinopathy predicts cardiovascular disease independently of subclinical atherosclerosis in individuals with type 2 diabetes: A prospective cohort study
por: Castelblanco, Esmeralda, et al.
Publicado: (2022)

Does Combination Therapy With SGLT2 Inhibitors and Renin–Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?
por: Zhao, Li-Min, et al.
Publicado: (2021)

SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis
por: Yang, Danning, et al.
Publicado: (2022)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
por: Mui, Jonathan V., et al.
Publicado: (2021)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Editorial: Recent advancement of the cardio-renal protective effects of SGLT2 inhibitors in people with and without diabetes
por: Kuriyama, Satoru, et al.
Publicado: (2023)

Possible renoprotective mechanisms of SGLT2 inhibitors
por: Nishiyama, Akira, et al.
Publicado: (2023)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study
por: Chang, Ting-Yung, et al.
Publicado: (2022)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
por: Du, Lixin, et al.
Publicado: (2022)

Wnt2 Contributes to the Development of Atherosclerosis
por: Zhang, Jinyu, et al.
Publicado: (2021)

COVID-19 and atrial fibrillation: Intercepting lines
por: Donniacuo, Maria, et al.
Publicado: (2023)

Editorial: New insights and future prospects of atrial cardiomyopathy
por: Li, Yan-Guang
Publicado: (2023)

The effect of SGLT2i on in-hospital acute heart failure risk in acute myocardial infarction patients—a retrospective study
por: Zhu, Yi, et al.
Publicado: (2023)

Editorial: Old habits die hard: from risk calculators and stenosis evaluation to phenotyping coronary atherosclerosis using cardiac CT
por: Slipczuk, Leandro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ssqf9tqctvva3eprlufclu4ojg